TNFSF10, TNF superfamily member 10, 8743

N. diseases: 445; N. variants: 10
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 AlteredExpression disease BEFREE DPSC‑differentiated osteoblasts expressing high TRAIL levels were capable to affect the cell viability of the human myeloma cell line H929, thus representing an effective anticancer therapeutic method. 29484421 2018
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 Biomarker disease BEFREE The experiments provide a rationale for possible future applications of IL2-αCD38-αCD38-scTRAIL for the treatment of patients with MM or other CD38-positive malignancies. 29982719 2018
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 Biomarker disease BEFREE Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in vivo in a mouse xenogtraft model. 27998762 2017
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 Biomarker disease BEFREE The cytotoxic effect of pIL6-TRAIL <sup>+</sup> -GFP <sup>+</sup> -UC-MSCs on MM growth was evaluated in SCID mice by bioluminescence and ex vivo by caspase-3 activation and X-ray imaging. 28962646 2017
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 AlteredExpression disease BEFREE Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma. 26378933 2015
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 GeneticVariation disease BEFREE In conclusion, rhTRAIL D269H/E195R is a potential therapy for multiple myeloma due to its high effectiveness and diminished binding to OPG. 24280212 2014
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 Biomarker disease BEFREE However, the susceptibility of MM cells to TRAIL is largely low in most of MM cells by yet largely unknown mechanisms. 22389670 2012
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 GeneticVariation disease BEFREE Because p53 directly modulates expression of death receptors, we investigated here whether p53 can modulate myeloma sensitivity to TRAIL. 22738917 2012
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 Biomarker disease BEFREE Different MM cell lines were assessed for their sensitivity to recombinant human (rh) TRAIL alone and in combination with the proteasome inhibitor bortezomib, which was shown to enhance the effect of rhTRAIL. 22420897 2012
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 Biomarker disease BEFREE Pretreatment with bortezomib effectively overcomes APO2L/TRAIL apoptosis resistance in myeloma cell lines and in CD138+ cells while directly adhered or in transwell assay. 19922463 2010
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 AlteredExpression disease BEFREE More importantly, these molecular changes induced by ATO-treated myeloma cells are very similar to the baseline expression pattern of hyperdiploid myeloma, which has a relative good prognosis with high expression of TRAIL and interferon related genes. 20953137 2010
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 Biomarker disease BEFREE PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL. 19749795 2009
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 Biomarker disease BEFREE Flavopiridol pretreatment synergized TRAIL-induced apoptosis in human myeloma and breast cancer cells. 17187253 2007
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 PosttranslationalModification disease BEFREE TRAIL expression up-regulated by interferon-gamma via phosphorylation of STAT1 induces myeloma cell death. 17201122 2007
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 Biomarker disease BEFREE TRAIL has been proposed to mediate IFN-alpha2b apoptosis in myeloma. 17823654 2007
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 AlteredExpression disease LHGDN Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. 16026644 2005
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 AlteredExpression disease BEFREE Our results highlight that MM T cells support OC formation and survival, possibly involving OPG/TRAIL interaction and unbalanced OC expression of TRAIL death and decoy receptors. 15308561 2004
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 AlteredExpression disease LHGDN Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. 11830480 2002
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 Biomarker disease LHGDN Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. 11877293 2002
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 Biomarker disease BEFREE Replication deficient Ad-p53 and human recombinant Apo2L/TRAIL were used.Myeloma cells with mutated/w.t. p53 and varying expression of bcl-2 were used to test the effect of Ad-p53, Apo2L/TRAIL, or both, on apoptosis, measured by annexin V. 11495702 2001
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 AlteredExpression disease LHGDN These results warrant further clinical studies with IFNs and Apo2L in MM. 11568006 2001
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 AlteredExpression disease BEFREE We conclude that myeloma cell expression of death effector receptors for TRAIL is insufficient to confer sensitivity to TRAIL-induced apoptosis but that in a significant minority of patients, irrespective of prior therapy, tumour cells are sensitive to TRAIL. 11587225 2001
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.100 Biomarker disease BEFREE Furthermore, we provide first time evidence that similar to Fas, TRAIL-induced apoptosis is not blocked by bcl-2 in MM cell lines. 10557057 1999